Hummingbird Bioscience raises $125m in Series C financing
Danish Novo Holdings A/S has led an oversubscribed US$125m Series C into the cancer antibody specialist Hummingbird Bioscience.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
BD installs production hub in Zaraogza
/in News/by Thomas GabrielczykBD will build a 165m manufacturing facility in Zaragoza, Spain to support the growth of its pre-filled drug delivery business.
COVID-19 therapeutics: Germany launches 300m funding
/in News/by Thomas GabrielczykGerman government has launched a 300m programme designed to bring clinically tested COVID-19 treatments to the patient’s bedside.
Recombinant silk producer AMSilk raises 29m
/in News/by Thomas GabrielczykAMSilk GmbH has closed a Series C financing at 29m to accelerate and expand commercialisation of its microbially produced silk fibres.
SARS-CoV-2-antibodies may promote severe COVID-19
/in News/by Thomas GabrielczykImmunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
Abingworth raises $582m for late-stage fund ACCD 2
/in News/by Thomas GabrielczykInternational life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.
USA supports to temporarily waive IP of COVID-19 vaccines
/in News/by Thomas GabrielczykThe Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.
Swiss Oculis SA raises $57m in Series C
/in News/by Thomas GabrielczykTopical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.
Mogrifiy completes Series A financing round
/in News/by Thomas GabrielczykCell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.
COVID-19 vaccine for poor countries
/in News/by Thomas GabrielczykModerna Inc. has signed a COVID-19 vaccine supply agreement with vaccination alliance Gavi.